Compare EPR Properties (EPR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Merck & Co., Inc. — how do they compare? EPR Properties trades at $54.93 (market cap $4.17B), while Merck & Co., Inc. trades at $146.45 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 84.2× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.84%). Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 45 Days and Merck & Co., Inc. for 98 Days on average.
| EPR | MRK | |
|---|---|---|
Market Cap | $4.17B | $351.28B |
Volume | 992,716 | 7,969,665 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $156.43 |
52-Week Low | $48.71 | $82.49 |
Typical Hold Time | 45 Days | 98 Days |
Enterprise Value | $7.68B | $398.04B |
Dividend Yield | 6.84% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $54.49, up 0.76% today, with a bearish technical signal but oversold oscillators suggesting potential reversal. The REIT shows strong profitability with a 37.66% net income margin and a 6.5% dividend yield, though earnings have been mixed with a recent miss in Q1 2026. Analysts maintain a consensus Buy rating with a $65.50 price target, implying significant upside from current levels.
The outlook is cautiously optimistic given the high dividend yield and discounted valuation, but risks include exposure to interest rate sensitivity and tenant performance in its experiential real estate portfolio. Near-term catalysts include the Q3 2026 earnings release on October 28, 2026, which could validate the company's growth trajectory amid a challenging macro environment.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
